R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-κB pathway

International Journal of Cancer

Volumn 124, Issue 11, 2009, Pages 2728-2736

  Festa, Michela ^a   Petrella, Antonello ^a   Alfano, Silvia ^a   Parente, Luca ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Apoptosis; NF B; Roscovitine; Thyroid cancer; TRAIL

Indexed keywords

CASPASE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; R ROSCOVITINE; ROSCOVITINE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR DR5; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; CASPASE 3; PROTEIN BCL X; PURINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TRANSLOCATION LINE; ACTIVE TRANSPORT; CARCINOMA; CELL DIVISION; METABOLISM; PATHOLOGY; PHYSIOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CARCINOMA; CASPASE 3; CELL DIVISION; CELL LINE, TUMOR; G2 PHASE; HUMANS; I-KAPPA B KINASE; NF-KAPPA B; PURINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 64249131546     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24260     Document Type: Article

References (37)

1. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-156 (Pubitemid 32126359)
2. Sherman SI. Thyroid carcinoma. Lancet 2003;367:501-511 (Pubitemid 36173719)
3. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol 2002;3:407-411 (Pubitemid 36958271)
4. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-231 (Pubitemid 33741897)
5. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-149 (Pubitemid 36808270)
6. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008;29:16-21.
7. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, Kaelin WG Jr. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 2004;10:643-648 (Pubitemid 38796857)
8. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-468
9. de la Motte S, Gianella-Borradori A. Pharmacokinetic model of Rroscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 2004;42:232-239 (Pubitemid 38477439)
10. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37. (Pubitemid 46094635)
11. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, Gray M, Crescenzi E, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006;12:1056-1064 (Pubitemid 44353387)
12. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75. (Pubitemid 36511833)
13. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163 (Pubitemid 29068521)
14. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000;60:4122-4129 (Pubitemid 30636594)
15. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436 (Pubitemid 44050137)
16. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999;18:6910-6924
17. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241-246 (Pubitemid 32157954)
18. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-227
19. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996;274:782-784 (Pubitemid 26398258)
20. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006;5:2251-2260 (Pubitemid 44530462)
21. Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-6947
22. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M, Fusco A. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997;15:1987-1994 (Pubitemid 27480687)
23. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S, et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 2004;279:54610-54619 (Pubitemid 40053204)
24. Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S. Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2004;89:410-418 (Pubitemid 38183911)
25. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 2008;15:263-273
26. Kim EH, Kim SU, Shin DY, Choi KS. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004;23:446-456 (Pubitemid 38174999)
27. Ortiz-Ferrón G, Yerbes R, Eramo A, López-Pérez AI, De Maria R, López-Rivas A. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 2008;18:664-676
28. Petrella A, Festa M, Ercolino SF, Zerilli M, Stassi G, Solito E, Parente L. Annexin-1 downregulation in thyroid cancer correlates to the degree of tumor differentiation. Cancer Biol Ther 2006;5:643-647 (Pubitemid 44024719)
29. Petrella A, Ercolino SF, Festa M, Gentilella A, Tosco A, Conzen SD, Parente L. Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. Eur J Cancer 2006;42:3287-3293 (Pubitemid 44854519)
30. Petrella A, D'Acunto CW, Rodriquez M, Festa M, Tosco A, Bruno I, Terracciano S, Taddei M, Paloma LG, Parente L. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur J Cancer 2008;44:740-749
31. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995;270:14255-14258
32. Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A, Vigneri P. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006;66:4263-4272
33. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular- cell neoplasia. Nat Rev Cancer 2006;6:292-306.
34. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003;63:1059-1066 (Pubitemid 36278439)
35. Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 2008;283:25003-25013
36. Mezosi E, Wang SH, Utsugi S, Bajnok L, Bretz JD, Gauger PG, Thompson NW, Baker JR, Jr. Interleukin-1β and tumor necrosis factor (TNF)-α sensitize human thyroid epithelial cells to. TNF-related apoptosis- inducing ligand-induced apoptosis through increases in procaspase- 7 and bid, and the down-regulation of p44/42mitogen-activated protein kinase activity. J Clin Endocrinol Metab 2004;89:250-257 (Pubitemid 38183890)
37. Kim YH, Lee DH, Jeong JH, Guo ZS, Lee YJ. Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol 2008;75:1946-1958